Current and Emerging Chemotherapy Treatment Strategies for Wilms Tumor in North America

Wilms tumor is the most common primary renal malignancy occurring in childhood. Approximately 500 children are diagnosed with Wilms tumor annually in the US alone, most of whom are aged 90% for patients with tumors of favorable histology. However, the treatment of patients with Wilms tumor with anap...

Full description

Saved in:
Bibliographic Details
Published in:Paediatric drugs 2008, Vol.10 (2), p.115-124
Main Authors: Gratias, Eric J., Dome, Jeffrey S.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Chemotherapy
Combined Modality Therapy
Diagnosis
Drug therapy
Humans
Internal Medicine
Kidney Neoplasms - drug therapy
Kidney Neoplasms - radiotherapy
Kidney Neoplasms - surgery
Medicine
Medicine & Public Health
Nephrectomy
Nephroblastoma
North America
Patient outcomes
Pediatrics
Pharmacotherapy
Prognosis
Risk factors
Therapy In Practice
Wilms Tumor - drug therapy
Wilms Tumor - radiotherapy
Wilms Tumor - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Wilms tumor is the most common primary renal malignancy occurring in childhood. Approximately 500 children are diagnosed with Wilms tumor annually in the US alone, most of whom are aged 90% for patients with tumors of favorable histology. However, the treatment of patients with Wilms tumor with anaplastic histology remains challenging. The optimal treatment strategies for Wilms tumor in relapse will be studied via international collaboration in the near future. Goals of emerging studies include minimizing toxicity while maintaining the outstanding cure rates for patients with a good prognosis and, through advancing biologic understanding and developing novel therapeutic approaches, improving the prognosis for those patients in whom effective cure of their disease continues to elude physicians.
ISSN:1174-5878
1179-2019
DOI:10.2165/00148581-200810020-00006